Sorry, you need to enable JavaScript to visit this website.

Antidote Treatment Nerve Agent, Auto-Injector (ATNAA)

(atropine and pralidoxime chloride injection)

 
 

You Are Now Leaving the MeridianMeds.com Website

Links to other sites are provided as a convenience to the viewer.

Pfizer accepts no responsibility for the content of linked sites.

CANCEL
Product image Mobile

The ATNAA is a specially designed unit for self- or buddy-administration by military personnel. Atropine and pralidoxime chloride are administered sequentially to counteract organophosphorus nerve agents. While a victim can administer their own injection, a second or third injection might be needed and should be administered by a buddy.1

Product indication

Indication:

ATNAA is indicated for the treatment of poisoning by susceptible organophosphorus nerve agents having anticholinesterase activity in adults. ATNAA is intended for use by Military Personnel. If feasible and appropriate, advise service member that ATNAA is an initial emergency treatment, that they need additional care at a healthcare facility.

This product is only available for use by United States military personnel.

Product Especification
To order or request a quote, call 1-800-638-8093
Key Product Specifications2:
NSN 6505-01-362-7427
NDC 11704-777-01
Delivers 2.1 mg atropine in 0.7 mL and 600 mg pralidoxime chloride in 2 mL sequentially through a single needle using the two-chambered BinaJect® drug delivery system.
Length of Unit 145 mm
Diameter of Unit 19 mm
Needle Gauge 23
Needle Length 21 mm
Administration Type Intramuscular injection
Packaged 100 auto-injectors per box
Packaging for Shipping

100 units per box
(311 mm x 210 mm x 244 mm), weighing 5 kg

2 interior boxes (200 units) per shipper box
(441 mm x 323 mm x 265 mm), weighing 10 kg

Storage Store at 25°C (77°F); excursions permitted to 15°C-30°C (59°F-86°F) [See USP Controlled Room Temperature]. Keep from freezing. Protect from light.
Prescription Required Yes

 

For medical

Adverse Event or Product Quality Complaints
If you wish to report an adverse event or product quality complaint, please call 1-800-438-1985.

For medical questions concerning Meridian products, to report an adverse event, or to speak to a member of Pfizer US Medical Information, please call 1-800-438-1985.

You are encouraged to report side effects of prescription drugs to the FDA.
Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.

Medical Information
If you have a medical question concerning Meridian products, please call 1-800-438-1985.
US HCPs can visit www.pfizermedinfo.com.

Product image Desktop
Product trademark

 

IMPORTANT SAFETY INFORMATION AND INDICATION
<p><strong>ATNAA (atropine and pralidoxime chloride injection), for intramuscular use</strong></p> <p><strong>Cardiovascular risks</strong> include tachycardia, palpitations, premature ventricular contractions, flutter, fibrillation, asystole, and myocardial infarction. Other cardiovascular adverse reactions have also been reported. Use caution in patients with known CV disease or conduction problems.</p> <p><strong>Heat injury</strong> may occur. Atropine may inhibit sweating and lead to hyperthermia. Avoid excessive exercising and heat exposure.</p> <p><strong>Acute glaucoma</strong> may be precipitated in susceptible individuals, and therefore ATNAA should be administered with caution in patients at risk for acute glaucoma.</p> <p>Administer with caution in patients with bladder outflow obstruction as <strong>urinary retention</strong> may occur.</p> <p>ATNAA should be administered with caution in patients with partial <strong>pyloric stenosis</strong> because of the risk of complete pyloric obstruction.</p> <p>Atropine may cause inspiration of bronchial secretions and formation of dangerous viscid plugs and may <strong>exacerbate chronic lung disease</strong>. Monitor respiratory status.</p> <p>Common adverse reactions of atropine include dryness of the mouth, blurred vision, dry eyes, photophobia, confusion, headache, and dizziness, among others. The common adverse reactions of pralidoxime chloride include changes in vision, dizziness, headache, drowsiness, nausea, tachycardia, increased blood pressure, muscular weakness, dry mouth, emesis, rash, dry skin, hyperventilation, decreased renal function, excitement, manic behavior, and transient elevation of liver enzymes and creatine phosphokinase.</p> <p>Muscle tightness and pain may occur at the injection site.</p> <p>Patients who have received succinylcholine and mivacurium may exhibit an accelerated reversal of the neuromuscular blocking effects when treated with ATNAA. Monitor neuromuscular effects with concomitant administration.</p> <p>Geriatric patients may be more susceptible to the effects of atropine.</p> <p>Pralidoxime chloride can cause decreased renal function. Patients with severe renal impairment may require less frequent doses after the initial dose.</p> <p>Patients with severe hepatic impairment may require less frequent doses after the initial dose.</p> <p>For optimal reactivation of organophosphorus-inhibited cholinesterase, the ATNAA should be administered as soon as possible after appearance of symptoms of organophosphorus nerve agent poisoning. ATNAA should be self- or buddy–administered by service members after donning protective mask and hood at the first sign of a chemical attack, and only if some or all of the mild symptoms of organophosphorus nerve agent exposure are present.</p>
<p class="title-indication"><strong>Indication<span class="colon">:</span></strong></p> <p>ATNAA is indicated for the treatment of poisoning by susceptible organophosphorus nerve agents having anticholinesterase activity in adults. ATNAA is intended for use by Military Personnel. If feasible and appropriate, advise service member that ATNAA is an initial emergency treatment, that they need additional care at a healthcare facility.</p> <p><strong>This product is only available for use by United States military personnel.</strong></p> <p class="indication-pi-link">Please see full <a href="/sites/default/files/inline-files/ATNAA%20USPI_MAY2020_0.pdf" target="_blank">Prescribing Information</a>.</p>
Important Safety Information and Indication